Novartis Exits Indian Arm in Rs 1,446 Crore Deal with ChrysCapital

Novartis AG Divests Stake in Indian Listed Entity

Swiss pharmaceutical major Novartis AG has announced its decision to sell its entire 70.68% stake in its publicly listed Indian subsidiary, Novartis India Ltd. The stake will be acquired by a consortium led by private equity firm ChrysCapital for a total consideration of Rs 1,446 crore. This move follows a strategic review initiated by Novartis AG in February 2024, aimed at refining its global operations and focusing on core areas of innovation.

The transaction has triggered a mandatory open offer for public shareholders, providing them an opportunity to sell their shares as part of the change in management control. The deal underscores a growing trend of multinational corporations restructuring their presence in India to align with global strategies, while also highlighting private equity's continued interest in the Indian pharmaceutical market.

Details of the Transaction

The agreement involves the sale of Novartis AG's complete holding in Novartis India Ltd to an investor group that includes ChrysCapital, WaveRise Investments, and Two Infinity Partners. The deal values the 70.68% stake at approximately Rs 1,446 crore. As per regulatory requirements, the acquisition has prompted a mandatory open offer to the public shareholders of Novartis India.

The consortium will offer to buy an additional 26% of the company's equity, which amounts to 64.19 lakh shares, from the public. The offer price has been set at Rs 860.64 per share, with the total value of the open offer potentially reaching Rs 552.50 crore if fully subscribed. The completion of the transaction is subject to standard closing conditions and is anticipated to be finalized in the third quarter of 2026.

Strategic Rationale for the Divestment

Novartis AG stated that this divestment is a key step in its transformation into a "pure-play innovative medicines company." The decision was made after a comprehensive strategic review of its operations. By selling its stake in the listed entity, which primarily handles established brands, Novartis aims to streamline its global footprint for more efficient and sustainable long-term growth.

The company has clarified that this sale does not mark a complete exit from the country. Novartis will maintain a significant presence in India through its wholly-owned subsidiary, Novartis Healthcare Pvt Ltd (NHPL). This entity manages the company's global capability centre in Hyderabad, research and development activities, and the commercial operations for its innovative medicines portfolio.

Market Reacts Positively to the Announcement

News of the acquisition was met with strong investor enthusiasm. Shares of Novartis India surged 20% on the Bombay Stock Exchange (BSE), hitting the daily upper trading limit to close at Rs 996.5 per share. This performance significantly outpaced the benchmark Sensex, which saw a modest gain of 0.38% on the same day. The sharp rise in share price reflects market approval of the deal and the potential for value unlocking under the new ownership.

Financial Performance and Challenges

The stake sale occurs as Novartis India has been navigating a period of declining sales. According to data from market research firm PharmaTrac, the company's 12-month sales value decreased from Rs 655 crore as of December 2022 to Rs 493 crore by December 2025. A major contributor to this decline has been the performance of its blockbuster heart failure drug, Vymada.

Sales of Vymada fell from Rs 258 crore to Rs 180 crore over the same period. The drug, once a key revenue driver, has faced increasing competition from generic alternatives after going off-patent. This has put pressure on the company's overall financial performance and likely influenced the parent company's decision to divest the unit.

Novartis's Continued Commitment to India

Despite selling its listed arm, Novartis AG remains committed to its operations in India through Novartis Healthcare Pvt Ltd. This unlisted entity is a crucial part of the company's global network, employing over 9,000 people, which constitutes about 11% of its global workforce. NHPL focuses on early-stage research, clinical trials across more than 300 sites in India, and the commercialization of its innovative product pipeline, particularly in oncology and cardio-renal metabolic therapies.

Impact on Existing Partnerships

In 2022, Novartis India entered into an agreement with Dr. Reddy's Laboratories for the exclusive sales and distribution of some of its established brands, including the popular pain medication Voveran. It is not yet clear how the change in ownership will impact this in-licensing agreement. The new management under ChrysCapital will need to address the future of such existing commercial partnerships.

Analysis and Industry Outlook

The acquisition by ChrysCapital, a major private equity player with a history of investing in the Indian healthcare sector, signals strong investor confidence in the potential of established pharmaceutical brands in the country. The deal also reflects a broader trend among multinational corporations to separate their legacy product portfolios from their core innovation and R&D engines. This allows them to focus resources on developing new, high-margin therapies while monetizing established but slower-growing assets. For the Indian pharmaceutical market, such transactions can bring in new capital and management focus to reinvigorate legacy brands.

Conclusion

The sale of Novartis AG's stake in its Indian listed entity to ChrysCapital for Rs 1,446 crore is a strategic move to align with its global focus on innovative medicines. While the deal marks the exit of Novartis from its publicly traded arm in India, the company will continue to operate and invest in the country through its R&D and commercial operations under Novartis Healthcare Pvt Ltd. The transaction, expected to close in late 2026, sets the stage for a new chapter for Novartis India under private equity ownership.